Life Sciences industry leader joins the region’s Life Science & Healthcare membership organisation
Cambridge, UK: 10 April 2024
From Research to Recovery in Neuroscience
The conference will highlight the North's strengths in neuroscience research, development and commercialisation, showcasing progress across a range of neurological diseases and conditions. Attendees will explore key challenges and opportunities, including:
Pioneer Group, a specialist in life science infrastructure and venture building, and global biopharmaceutical company AbbVie, have crowned Alceus Bio the winner of their 2025 Golden Ticket programme.
The initiative is designed to support breakthrough scientific discovery with the potential to advance human health and accelerate companies developing novel, transformational therapies and innovations for immunology, oncology, neurology, eye care, aesthetics, or other specialities including obesity, GI and hepatology.
Hosted by Bionow, the 2026 Pharma Manufacturing conference returns to bring together industry leaders, academic innovators and regulatory experts, all united by a shared commitment to shape the future of pharma manufacturing in the North. Through thought-provoking talks, panel discussions and high-impact networking, attendees will explore both the obstacles and the opportunities ahead.
Bridging Life Sciences and Artificial Intelligence
AI is rapidly reshaping the life sciences sector, from accelerating drug discovery to transforming diagnostics and personalising treatment pathways. The 2026 Bionow BioAI Summit brings together experts from industry, academia and healthcare to explore how AI is being applied across the sector and where it can deliver the most impact. Join us to connect and share insight around the future of AI.
Connecting Innovation, Talent and Opportunity in the Heart of the North
Join us for the inaugural York and North Yorkshire Life Sciences Forum, a new event bringing together leading health and life sciences businesses, academic innovators, investors and policymakers to shape the future of the sector in one of the UK's most promising emerging clusters, as part of the York and North Yorkshire Health and Life Sciences Cluster Mobilisation Project.
About the event
Stevenage, UK, 8 January 2026 - NRG Therapeutics Ltd. (“NRG”), a clinical stage neuroscience company targeting a novel mechanism to rectify mitochondrial dysfunction in neurodegenerative diseases, is pleased to announce that the first participants have been dosed in its first-in-human Phase 1 clinical trial of its lead candidate NRG5051 which is being developed as a treatment for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) and Parkinson’s.
Change in role from Chief Data Officer reflects Qureight’s continued growth and commercial success in delivering customers’ clinical studies